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by gavage. Serum HBV DNA and HBsAg levels were determined by fluorescence-based PCR and enzymelinked immune sorbent assay, respectively. HBV S gene expression amounts were assessed by reverse transcription polymerase chain reaction. Positive rates of HBsAg in liver cells were evaluated immunohistochemistry.
RESULTS
Average rate reductions of HBsAg after treatment on the 3 rd , 5 th , and 7 th days were 32.34%, 45.96%, and 59.15%, respectively. The inhibitory effect of antigene-LNA on serum HBsAg peaked on day 7, with statistically significant differences compared with pretreatment (0.96 ± 0.18 vs 2.35 ± 0.33, P < 0.05) and control values (P < 0.05 for all). Average reduction rates of HBV DNA on the 3 rd , 5 th , and 7 th days were 38.55%, 50.95%, and 62.26%, respectively. This inhibitory effect peaked on the 7 th day after treatment with anti-gene-LNA, with statistically significant differences compared with pre-treatment (4.17 ± 1.29 vs 11 .05 ± 1.25, P < 0.05) and control values (P < 0.05 for all). The mRNA levels of the HBV S gene (P < 0.05 for all) and rates of HBsAg positive liver cells (P < 0.05 for all) were significantly reduced compared with the control groups. Liver and kidney function, and histology showed no abnormalities.
INTRODUCTION
Hepatitis B virus (HBV) is one of the most severe human infectious virus in the world. According to estimates, 240 million individuals globally are chronically infected with HBV [1] . In the past few years the prevalence of chr onic HBV infection shows a declining trend throughout the world because of an antiHBV vaccine and the imp lementation of successful immunization programs in enzootic zones. Despite improvement in global access to vaccination and treatment, mortality levels remain high [2, 3] . Chronic hepatitis B can be effectively and safely treated but a cure remains elusive.
The HBV genome is surrounded by an envelope containing HBV surface antigen (HBsAg) and HBV core antigen (HBcAg) and is a relaxed circular and pa rtially doublestranded DNA [4] . In the nuclei of infected hepatocytes, covalently closed circular DNA (cccDNA) is compounded and sustained at low replication levels are infected with HBV; cccDNA plays a role as the transcription template for all HBV RNAs [5] . Due to cccDNA persistence in a stable form within the hepatocyte nucleus, it remains to a great extent unaffected by current therapies. One of the most important antiviral Drugs includes nucleus(t)ide analogues (NAs) and PEGylated/nonPEGylated interferonalpha (IFNα) are widely used to limit viral replication in chronic hepatitis B (CHB) infection [6] . NAs therapy via a direct effect on DNA polymerase activity to some extent notably reduces viral load [7] . Unfortunately, due to somewhat poor response and/or drug resistance, these therapies without achieve a therapeutic effect [8] . Therefore, the development of a novel therapeutic strategy to repress HBV replication is of great significance in saving lives of CHB patients.
Recently, antisenseLNA was shown to effectively inhibit HBV replication and expression in vitro mod els [9] . However, antisense therapy cannot cut off the replication and transcription of viral genes from the source. It can only interfere with the synthesis of viral protein at the level of expression, and is prone to stop drug rebound. In antigene therapy, triplexforming oligonucleotides (TFOs) provides a promising approach to bind in the major groove of duplex DNA at polypurine or polypyrimidine stretches in a sequencespecific manner [10] . TFOs prevent the association of target DNA, polymerase, and transcription factors, downregulating target genes [1113] . A recent and promising technological progress is the development of locked nucleic acid (LNA), which not only enhances binding to its target sequence while being resistant to nuclease degradation, but also shows minimal toxicity [1416] . Compared with antisense therapy, it has the advantage of blocking virus gene replication and transcription from the source.
The aim of this study was to design liposome based transport of a LNA modified oligonucleotide to inhibit HBV DNA express in transgenic mice, the final objective was to assess the antiviral effects of HBV S gene-specific antigene LNA in transgenic mice.
MATERIALS AND METHODS

Anti-gene-LNA synthesis and modification
According to the HBV S encoding chain, antigene LNA was designed using the Walk function of the RNA structure software to select ΔG37 value of small frag ments; by Blast analysis and homology sequence features, the synthesis and modification of antigene LNA (5'TaccTcTtgtA3'; uppercase and lower case letters represent LNA and DNA, respectively) were per formed by Shanghai biotechnology limited company.
Animals
HBV transgenic mice (n = 35; 18 males and 17 females) weighing 1923 g were purchased from the Guangzhou Military Air Force Hospital of the People's Liberation Army of China. All mice were positive for serum HBsAg and HBV DNA. They were bred and housed in pathogenfree conditions at 25 ℃ ± 2 ℃ under a 12 h:12 h lightdark cycle, with food and water provided ad libitum unless otherwise specified. All animal care and experimental procedures were approved by the Institutional Ethnics Committee of Youjiang Medical College for Nationalities.
Mice were randomly divided into five groups (n = 7 each), including negative control (blank control, unrelated sequence control), positive control (lamivudine, antisenseLNA), and antigeneLNA experimental group. The lamivudine control group was administered daily gavage of 2 mg/kg for 7 d; the remaining groups were injected (400 μL 5% glucose-liposome containing the corresponding drug) via the tail vein at 1, 3, and 5 d, respectively. Blood samples were collected from the orbital vein before and after injection on 3 rd , 5 th and 7 th days, respectively, and centrifuged at 5000 r/min for 5min. The resulting serum was stored at 20 ℃ until use. On the 7 th day, all mice were sacrificed by cervical dislocation under anesthesia. Liver and kidney samples were obtained for histological assessments, ultrastructural examinations, and immunohistochemistry.
Measurement of serum HBsAg levels by enzyme-linked immune sorbent assay
Serum HBsAg levels were quantified with an enzymelinked immune sorbent assay enzymelinked immune sorbent assay (ELISA) kit according to the manufacturer's protocol. ELISA kits were purchased from Lizhu Biology Company, Zhuhai, China.
Measurement of HBV DNA levels by Fluorescence based PCR
Serum HBV DNA levels were quantified with a diagnostic kit for the quantification of HBV DNA, according to the manufacturer's protocol. HBV DNA diagnostic kits were purchased from Daan Gene Company, Guangzhou, China. Briefly, 30 μL serum was added to 70 μL DNA extract and oscillated for 15 s, incubated at 100 ℃ for 10 min, and centrifuged at 12000 r/min for 5 min. 
Immunohistochemistry
To detect HBsAg in liver cells, the sections were dewax ed in xylene and rehydrated in graded alcohol. The endogenous peroxidase activity was suppressed by 3% hydrogen peroxide for 15 min. After rinsing twice in phosphatebuffered saline (PBS), antigen retrieval was performed by immersing the sections in 10 mmol/L sodium citrate buffer (pH 6.0) and heated for 15 min in a microwave oven. The sections were then treated for 4 ℃ for 18 h with mouse antiHBsAg monoclonal antibody (1:100). PBS was used as a negative control. After three washes with PBS, the sections were subsequently treated with biotinylated goat antirabbit immunoglobulin for 15 min and horseradish peroxidase streptavidin complex for 15 min. The slides were then washed three times with PBS and incubated in DAB for 5 min and counterstained with hematoxylin for 30 s. After dehydration with graded alcohol, the slides were mounted and analyzed under an Olympus BX53 inverted microscope (Olympus, Japan).
Histology
To assess the morphological changes of the liver and kidney, formalintreated tissue samples were paraffin embedded. Serial sections with 4 mm thickness were obtained and stained with hematoxylin and eosin (H 
Statistical analysis
Quantitative data are mean ± SD, and were analyzed with the SPSS 13.0 software. Groups were compared by oneway analysis of variance (ANOVA) followed by the Tukey's multiple range post hoc test. P < 0.05 was considered statistically significant. Figure 1A ).
RESULTS
Serum HBsAg levels
HBV DNA levels
The inhibitory effect of antigeneLNA on HBV DNA was analyzed by fluorescence based PCR on the 3 
HBV S gene expression levels in the liver
The average grayscale values of lanes 15 for HBV SDNA (with GAPDH set to 1) were 1, 0.96, 0.78, 0.51, and 0.32, respectively. Quantitation of HBV S gene expression levels in the liver after treatment with anti geneLNA revealed a significant decrease compared with pretreatment (P < 0.05) or control (P < 0.05) values (Figure 2 ). Figure 3 shows representative immunohistochemical staining data for HBsAg positive cells in liver tissues. No significant differences were observed in the rates of HBsAg positive liver cells among the blank control, unrelated sequence control and lamivudine control groups. Meanwhile, 47% of liver cells were positive for HBsAg after treatment with antisenseLNA verify, a rate significantly lower than those of the blank control, unrelated sequence control, and lamivudine control groups (P < 0.05); the positive expression rate of HBsAg in liver cells in the antigeneLNA treatment group was 31%, significantly lower than those of all control groups (P < 0.05)
HBsAg positive cells in liver tissues
Histological observations
H&E staining was used to assess the effects of anti geneLNA and liposomes on the histological features of the liver and kidney. Liver and kidney sections stained with H and E showed no significant differences between the antigeneLNA group and controls, suggesting that antigeneLNA had no obvious toxicity on liver and kidney at the histological level (Figures 4 and 5) .
DISCUSSION
The present study assessed serum HBsAg, HBV DNA, and HBV S gene expression levels in transgenic mice. The results demonstrated that HBV amounts were significantly reduced after injection of antigene LNA on 7 th day, shows a significant difference compared with before treatment and control groups (P < 0.05).
Significantly less positive HBsAg cells in liver tissues were obtained after treatment with antigeneLNA compared with the control groups, indicating that anti geneLNA transacted by cationic liposomes can effe ctively enter nucleolus in the liver of transgenic mice after tail vein injection and play a role in reducing HBV DNA replication and transcription. We successfully used antisenseLNA to inhibit the translation and expression of HBV mRNA in vitro and in vivo models in previous study [15] , due to the basic principle of antisenseLNA targeting specific mRNAs by annealing complementary oligonucleotides [1720] . In the simplest form, antisenseLNAs are introduced into the liver cell to downregulate gene expression by interfering with the translation of mRNA instead of DNA transcription, i.e., they are involved in posttran scriptional rather than transcriptional gene regulation. Therefore, treatment with antisenseLNA does not achieve satisfactory effects. TFOs have emerged as potential regulators of biological activity for direct modifications of genomic DNA at selected sites through mutagenesis or homologous recombination and changing the antigene therapeutic method [2123] . In the present study, antigeneLNA was assessed for its antiviral effects in transgenic mice. The results showed that the inhibitory effect of antigeneLNA peaked on the 7 th day, with a statistically significant difference compared with the antisenseLNA group (P < 0.05). However, compared with other nucleic acid based approaches, TFOs faces challenges such as olig onucleotides (ONs) targeting ability and the stability of the TFOs in a genomic context. In order to efficient, ON should increase target DNA selectively, easily, stability, and with high affinity. Until now, due to the low of affinity of TFOs or their DNA targets, the method of antigeneDNA hampered to downregulate and control the expression level of genomic DNA. The antigene LNA sugar unit not only significantly enhances triplex stability but also partly relieves sequence restriction constraints [2426] . The present study provided evidence that once in the nucleus, an integrated HBV DNA seq uence composed of LNA and DNA oligonucleotides (anti geneLNA) effectively targeted HBV, therefore inhibiting its replication at the transcription level.
HBV DNA is easily mutated compared to other DNA viruses during replication; one of the important reasons is that HBV DNA polymerase lacks a proofreading function [27] , which can cause HBV mutations to occur at a 10fold higher frequency [28] . This results in decreased susceptibility or increased resistance in antiHBV trea tment. HBV contains 4 overlapping open reading frames (ORFs) encoding the polymerase (P), core (C), surface antigen (S), and X proteins [29] . The S gene region is one of the most important open reading frames of the HBV genome, encoding a protein forming an important part of HbsAg [30, 31] . Thus, the S gene is not only clos ely associated with virus replication, transcription, assembly, and secretion processes, but also with cellular and humoral immune responses induced by the virus.
Taken together, this study showed an effective 
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